40.63
Kodiak Sciences Inc (KOD) 最新ニュース
Kodiak Sciences | 10-K: FY2025 Annual Report - Moomoo
Kodiak Sciences Faces Going Concern Warning As Valuation Gap Persists - Sahm
Lifesci Capital Trims Earnings Outlook for Kodiak Sciences - National Today
Q1 EPS Estimates for Kodiak Sciences Decreased by Analyst - MarketBeat
Lifesci Capital Forecasts Lower Earnings for Kodiak Sciences - MarketBeat
Kodiak Sciences CFO Borgeson sells $1.2m in shares By Investing.com - Investing.com India
Kodiak Sciences CFO Borgeson sells $1.2m in shares - Investing.com
Kodiak Sciences (KOD) CFO exercises 30K options and sells 30K shares under 10b5-1 plan - Stock Titan
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance UK
[144] Kodiak Sciences Inc. SEC Filing - Stock Titan
Point72 reports 609,806 shares in Kodiak (KOD) — 1.0% stake - Stock Titan
Kodiak Sciences Inc. (KOD) options chain - Yahoo Finance Singapore
Kodiak Sciences (KOD) Sees Decline as Stock Falls 8.7% - gurufocus.com
Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation - Moomoo
Kodiak Sciences Inc. (KOD) Latest Stock News & Headlines - Yahoo! Finance Canada
Fed Meeting: Can Kodiak Sciences Inc lead its sector in growthQuarterly Market Summary & Breakout Confirmation Trade Signals - baoquankhu1.vn
Kodiak Sciences 2025 Financial Update - AlphaStreet
Kodiak Sciences (KOD) Reports Positive Developments in Q4 Results - GuruFocus
Kodiak Sciences (KOD) Shares Surge Over 10% - GuruFocus
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus - TradingView
Kodiak Sciences Stock Soars Amid Positive Phase 3 Findings - StocksToTrade
Kodiak Sciences Stock (KOD) Rallies as Analysts Weigh In After Earnings - TipRanks
Why Kodiak Sciences Stock Is Suddenly Surging - TipRanks
Kodiak climbs on late-stage trial win for diabetic retinopathy therapy - MSN
Kodiak Sciences (NASDAQ:KOD) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Kodiak Sciences Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Kodiak Sciences (NASDAQ: KOD) outlines retinal pipeline and going-concern risk - Stock Titan
Phase 3 win and 2027 cash runway for Kodiak Sciences (NASDAQ: KOD) - stocktitan.net
Kodiak Sciences Q4 net loss widens on higher R&D spending - TradingView
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - Bitget
BRIEF-Kodiak Sciences Q4 Net Income USD -56.736 Million - TradingView
Press Release: Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Kodiak Sciences (NASDAQ:KOD) Trading 8.3% HigherHere's Why - MarketBeat
Kodiak Sciences stock is surging Friday: What's driving the action? - MSN
Kodiak Sciences (KOD) climbs 75% on stellar clinical results - msn.com
Kodiak Sciences stock hits 52-week highhere's why - MSN
MACD Signal: Can Kodiak Sciences Inc grow without dilution2026 Risk Factors & Real-Time Volume Spike Alerts - baoquankhu1.vn
Kodiak Sciences Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Kodiak Sciences (NASDAQ:KOD) Trading Down 7.8%Time to Sell? - MarketBeat
Kodiak Sciences: Road To $120 - Forbes
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing - AOL.com
Kodiak Sciences (KOD) Is Up 66.3% After Strong Zenkuda GLOW2 Phase 3 DataHas The Bull Case Changed? - Yahoo Finance
Kodiak Sciences (KOD) Is Up 66.3% After Zenkuda’s Phase 3 Win in Diabetic Retinopathy - simplywall.st
Kodiak Sciences (KOD) CEO exercises 300,000 stock options into common shares - Stock Titan
KOD Shares Surge Following Encouraging Phase III Results for Eye Disorder Treatment Candidate - Bitget
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate - The Globe and Mail
H.C. Wainwright raises Kodiak Sciences stock price target on trial data - Investing.com UK
Kodiak Sciences: A Promising Breakthrough in Diabetic Retinopathy Trials - timothysykes.com
Kodiak Sciences (NASDAQ:KOD) Shares Gap Up After Analyst Upgrade - MarketBeat
Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $80.00 - MarketBeat
Kodiak Sciences: Shares Up On Positive Eye Disease DataBut I Remain On Sidelines (KOD) - Seeking Alpha
H.C. Wainwright raises Kodiak Sciences stock price target on trial data By Investing.com - Investing.com India
Kodiak Sciences Inc. (NASDAQ:KOD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
大文字化:
|
ボリューム (24 時間):